These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 8873220)

  • 1. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
    Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
    Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic and functional variability of cytochrome P4502C9.
    Bhasker CR; Miners JO; Coulter S; Birkett DJ
    Pharmacogenetics; 1997 Feb; 7(1):51-8. PubMed ID: 9110362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H; Inoue K; Shimada T
    Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
    Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates.
    Takanashi K; Tainaka H; Kobayashi K; Yasumori T; Hosakawa M; Chiba K
    Pharmacogenetics; 2000 Mar; 10(2):95-104. PubMed ID: 10761997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.
    Kimura M; Ieiri I; Mamiya K; Urae A; Higuchi S
    Ther Drug Monit; 1998 Jun; 20(3):243-7. PubMed ID: 9631918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.
    Wang SL; Huang J; Lai MD; Tsai JJ
    Pharmacogenetics; 1995 Feb; 5(1):37-42. PubMed ID: 7773301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis.
    Ieiri I; Tainaka H; Morita T; Hadama A; Mamiya K; Hayashibara M; Ninomiya H; Ohmori S; Kitada M; Tashiro N; Higuchi S; Otsubo K
    Ther Drug Monit; 2000 Jun; 22(3):237-44. PubMed ID: 10850388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation.
    Gill HJ; Tjia JF; Kitteringham NR; Pirmohamed M; Back DJ; Park BK
    Pharmacogenetics; 1999 Feb; 9(1):43-53. PubMed ID: 10208642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
    London SJ; Daly AK; Leathart JB; Navidi WC; Idle JR
    Pharmacogenetics; 1996 Dec; 6(6):527-33. PubMed ID: 9014202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.
    Kidd RS; Straughn AB; Meyer MC; Blaisdell J; Goldstein JA; Dalton JT
    Pharmacogenetics; 1999 Feb; 9(1):71-80. PubMed ID: 10208645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
    Hanatani T; Fukuda T; Ikeda M; Imaoka S; Hiroi T; Funae Y; Azuma J
    Pharmacogenomics J; 2001; 1(4):288-92. PubMed ID: 11908770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.
    Goldstein JA; Faletto MB; Romkes-Sparks M; Sullivan T; Kitareewan S; Raucy JL; Lasker JM; Ghanayem BI
    Biochemistry; 1994 Feb; 33(7):1743-52. PubMed ID: 8110777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
    Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
    Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe.
    Kaminsky LS; de Morais SM; Faletto MB; Dunbar DA; Goldstein JA
    Mol Pharmacol; 1993 Feb; 43(2):234-9. PubMed ID: 8429826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
    Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
    Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.